UNSPSC 51181620: Thyromedan or tyromedan

This classification denotes a thyroid agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9MU67I9K5I. European Medicines Agency schedules Tyromedan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11370MIG. Tyromedan generally arises in the molecular formula C21H24I3NO4. The term TYROMEDAN is an International Non-Proprietary Name or INN. TYROMEDAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Thyromedan or tyromedan bears US NLM identifiers UMLS ID C2825356 and NCI Concept Code C80844. SMILES: CCN(CC)CCOC(=O)CC1=CC(=C(C(=C1)I)OC2=CC(=C(C=C2)OC)I)I.Cl.

UNSPSC 51181620 Thyromedan or tyromedan is a Commodity code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products for distribution across health-care and institutional facilities. The scope encompasses manufacturers supplying branded and generic drugs with specific National Drug Codes (NDC), detailed product specifications (SKUs, UPCs, strength, dosage form, packaging), and compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). Vendors must maintain contractual relationships with authorized drug wholesalers, support electronic data interchange (EDI) capability, and offer flexible pricing structures including flat price, net price formats, and WAC-minus options. State and local procurement under this code flows through cooperative purchasing alliances—notably multistate vehicles like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—that aggregate demand across participating state agencies and subordinate jurisdictions to achieve volume discounts and streamlined vendor management. Issuing bodies include state departments of administration and health, with contracts typically extending to multiple participating states.

The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP on January 20, 2026 (MMCAP RFP S1070000015802) seeking multiple-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. The solicitation emphasizes price competitiveness (weighted 75 percent of evaluation) and requires vendors to supply products through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must maintain commercial general liability insurance of $5 million per occurrence and network security and privacy liability of $2 million, pay a 3 percent administrative fee on all contract purchases, and accept performance penalties ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions, and the RFP does not identify specific set-aside restrictions. Geographic activity centers on Minnesota and participating states including Oregon; broader multistate participation through cooperative purchasing vehicles suggests activity across additional jurisdictions in the long tail.